GALLIUM GA-68 GOZETOTIDE for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 10 Jan 2020: Trial started, NCT07209878
  2. 7 Oct 2025: Trial registered, NCT07209878

The trials

NCT07209878: 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

State
Under way
Phase
Phase 2 and Phase 3
People
100 planned
Started
10 Jan 2020
Primary completion
31 Dec 2025
Arms
68Ga-PSMA-11 PET/CT
Results
None posted
  1. 10 Jan 2020: Trial started
  2. 7 Oct 2025: Trial registered

NCT07831824: Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])

State
Under way
Phase
Phase 2 and Phase 3
People
408 planned
Started
30 Sep 2026
Primary completion
30 Sep 2029
Arms
[68Ga]-LNTH-2401
Results
None posted
  1. 21 Sep 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 68Ga-PSMA-11, Gozellix, Locametz, Prostamedix.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.